Journal of Antimicrobial Chemotherapy, Vol 40, 503-509, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
AP MacGowan, KE Bowker, HA Holt, M Wootton and DS Reeves
The in-vitro activity of a new 8-methoxy-quinolone, Bay 12-8039, was
assessed against 218 anaerobic bacteria. Ninety-eight per cent of strains
belonging to the Bacteroides fragilis group (n = 65) were inhibited by <
or = 2 mg/L of Bay 12-8039 whereas 97%, 94%, 94% and 100%, respectively, of
Gram-negative bacilli (n = 93), non-sporing Gram- positive bacilli (n =
36), endospore-forming Gram-positive bacilli (n = 34) and Gram-positive
cocci (n = 45) were also inhibited by < or = 2 mg/L. Eighty-three per
cent of all anaerobes tested were inhibited by < or = 1 mg/L Bay 12-8039
and 99.5% by < or = 4 mg/L. When compared with ciprofloxacin,
clinafloxacin, ofloxacin and trovafloxacin, Bay 12-8039 was more active
than ciprofloxacin and ofloxacin, equipotent to trovafloxacin but not as
active as clinafloxacin.
ORIGINAL ARTICLES
Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria
Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust, UK. lesassays@uknequasaa.win-uk.net
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. J. C. Goldstein, D. M. Citron, Y. A. Warren, K. L. Tyrrell, C. V. Merriam, and H. Fernandez In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections Antimicrob. Agents Chemother., January 1, 2006; 50(1): 148 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Edmiston, C. J. Krepel, G. R. Seabrook, L. R. Somberg, A. Nakeeb, R. A. Cambria, and J. B. Towne In Vitro Activities of Moxifloxacin against 900 Aerobic and Anaerobic Surgical Isolates from Patients with Intra-Abdominal and Diabetic Foot Infections Antimicrob. Agents Chemother., March 1, 2004; 48(3): 1012 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Snydman, N. V. Jacobus, L. A. McDermott, R. Ruthazer, E. Goldstein, S. Finegold, L. Harrell, D. W. Hecht, S. Jenkins, C. Pierson, et al. In Vitro Activities of Newer Quinolones against Bacteroides Group Organisms Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3276 - 3279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Peterson, L. B. Hovde, D. H. Wright, G. H. Brown, A. D. Hoang, and J. C. Rotschafer Pharmacodynamics of Trovafloxacin and Levofloxacin against Bacteroides fragilis in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., January 1, 2002; 46(1): 203 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dali, E. R. Giugliano, E. M. Vellozzi, and M. A. Smith Susceptibilities of Propionibacterium acnes Ophthalmic Isolates to Moxifloxacin Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2969 - 2970. [Full Text]
|
|
|
|
|
|
H. Oh, N. El Amin, T. Davies, P. C. Appelbaum, and C. Edlund gyrA Mutations Associated with Quinolone Resistance in Bacteroides fragilis Group Strains Antimicrob. Agents Chemother., July 1, 2001; 45(7): 1977 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Jones, A. M. Staples, I. Critchley, C. Thornsberry, P. Heinze, H. D. Engler, and D. F. Sahm Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2645 - 2652. [Abstract] [Full Text]
|
|
|
|
|
|
R. Bachoual, L. Dubreuil, C.-J. Soussy, and J. Tankovic Roles of gyrA Mutations in Resistance of Clinical Isolates and In Vitro Mutants of Bacteroides fragilis to the New Fluoroquinolone Trovafloxacin Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1842 - 1845. [Abstract] [Full Text]
|
|
|
|
|
|
D. R. Snydman, N. V. Jacobus, L. A. McDermott, and S. E. Supran Comparative In Vitro Activities of Clinafloxacin and Trovafloxacin against 1,000 Isolates of Bacteroides fragilis Group: Effect of the Medium on Test Results Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1710 - 1712. [Abstract] [Full Text]
|
|
|
|
|
|
R. Schaumann, G. Ackermann, B. Pless, M. C. Claros, and A. C. Rodloff In Vitro Activities of Gatifloxacin, Two Other Quinolones, and Five Nonquinolone Antimicrobials against Obligately Anaerobic Bacteria Antimicrob. Agents Chemother., November 1, 1999; 43(11): 2783 - 2786. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Wilson, R. Kubin, I. Ballin, K.-M. Deppermann, H. P. Bassaris, P. Leophonte, A. J. M. Schreurs, A. Torres, and B. Sommerauer Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis J. Antimicrob. Chemother., October 1, 1999; 44(4): 501 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Peterson, L. B. Hovde, D. H. Wright, A. D. Hoang, J. K. Raddatz, P. J. Boysen, and J. C. Rotschafer Fluoroquinolone Resistance in Bacteroides fragilis following Sparfloxacin Exposure Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2251 - 2255. [Abstract] [Full Text]
|
|
|
|
|
|
C. Betriu, M. Gómez, M. L. Palau, A. Sánchez, and J. J. Picazo Activities of New Antimicrobial Agents (Trovafloxacin, Moxifloxacin, Sanfetrinem, and Quinupristin-Dalfopristin) against Bacteroides fragilis Group: Comparison with the Activities of 14 Other Agents Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2320 - 2322. [Abstract] [Full Text]
|
|